Incannex Healthcare Inc. (IXHL)

NASDAQ: IXHL · Real-Time Price · USD
0.2100
-0.0100 (-4.55%)
At close: May 30, 2025, 4:00 PM
0.1910
-0.0190 (-9.05%)
After-hours: May 30, 2025, 7:59 PM EDT
-4.55%
Market Cap 19.68M
Revenue (ttm) 98,000
Net Income (ttm) -21.74M
Shares Out 93.70M
EPS (ttm) -1.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 28,705,123
Open 0.2093
Previous Close 0.2200
Day's Range 0.1960 - 0.2121
52-Week Range 0.0800 - 3.5500
Beta 2.24
Analysts n/a
Price Target n/a
Earnings Date May 15, 2025

About IXHL

Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research, development, manufacture, sale, and distribution of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that has completed Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It... [Read more]

Sector Healthcare
Founded 2001
Employees 9
Stock Exchange NASDAQ
Ticker Symbol IXHL
Full Company Profile

Financial Performance

Financial Statements

News

Incannex Healthcare Inc. Advances IHL-42X RePOSA Trial to Phase 3 Following FDA Protocol Clearance

NEW YORK and MELBOURNE, Australia, May 29, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage pharmaceutical company developing novel combination therapies, today annou...

1 day ago - GlobeNewsWire

Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 3Q 2025

Dallas, Texas--(Newsfile Corp. - May 28, 2025) - Incannex Healthcare Inc. (NASDAQ: IXHL): Stonegate Capital Partners updates their coverage on Incannex Healthcare Inc. (NASDAQ: IXHL). During the third...

2 days ago - Newsfile Corp

Incannex Healthcare Inc. Enters Agreement to Cancel Remaining Series A Warrants, Eliminating Up to 347.2 Million Shares from Potential Dilution Ahead of IHL-42X Phase 2 Topline Results

MELBOURNE, Australia and NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company advancing combination drug therapies for high-im...

2 days ago - GlobeNewsWire

Incannex Healthcare Inc. Executes Strategic Cancellation of 50.4% of Series A Warrants, Significantly Reducing Potential Dilution

Raises $12.5M via ATM to Strengthen Shareholder Position Ahead of IHL-42X Phase 2 Data Raises $12.5M via ATM to Strengthen Shareholder Position Ahead of IHL-42X Phase 2 Data

10 days ago - GlobeNewsWire

Incannex Announces Potential Reduction of Up to 50.4% of its Series A Warrants

NEW YORK and MELBOURNE, Australia, May 16, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (“Incannex”), a clinical-stage biopharmaceutical company leading the way in developing oral...

14 days ago - GlobeNewsWire

Incannex Healthcare Inc. Reports Fiscal Third Quarter 2025 Financial Results and Business Updates

NEW YORK and MELBOURNE, Australia, May 15, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing oral c...

15 days ago - GlobeNewsWire

Incannex Healthcare (IXHL) Stock Soars Over 800%: What's Going On?

Incannex Healthcare Inc IXHL shares surged 876% to 83 cents on Wednesday after the company announced the completion of patient dosing in the Phase 2 portion of its Phase 2/3 RePOSA trial for IHL-42X, ...

16 days ago - Benzinga

Incannex Healthcare Inc. Provides Clinical Program Update on IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)

Patient dosing completed in Phase 2 portion of Phase 2/3 RePOSA study evaluating IHL-42X oral treatment for OSA. End-of-study follow-up assessments on track for completion by May 17, 2025.

16 days ago - GlobeNewsWire

Incannex Healthcare Completes Phase 2 Enrollment in RePOSA Phase 2/3 Trial of IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)

NEW YORK and MELBOURNE, Australia, April 03, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing new ...

2 months ago - GlobeNewsWire

Incannex Healthcare Inc. Announces Pricing of $12.5 Million Private Placement Priced at the Market Under Nasdaq Rules

Funds to support the advancement of Incannex's IHL-42X Phase 2/3 Obstructive Sleep Apnea (OSA) clinical program through U.S. Phase 2 completion, topline readout, and its expansion into a global Phase ...

3 months ago - GlobeNewsWire

Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 2Q 2025

Dallas, Texas--(Newsfile Corp. - February 18, 2025) - Incannex Healthcare Inc. (NASDAQ: IXHL): Stonegate Capital Partners updates their coverage on Incannex Healthcare Inc. (NASDAQ: IXHL). During the ...

3 months ago - Newsfile Corp

Incannex Healthcare Inc. Reports Fiscal Second Quarter 2025 Financial Results and Business Updates

NEW YORK and MELBOURNE, Australia, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing oral ...

3 months ago - GlobeNewsWire

Incannex Healthcare Appoints Alison Wimms, Ph.D. to Newly Formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board

Dr. Wimms brings extensive industry and clinical development experience in sleep medicine innovation Dr. Wimms brings extensive industry and clinical development experience in sleep medicine innovatio...

4 months ago - GlobeNewsWire

Incannex Healthcare Announces Positive Topline Results from Pharmacokinetics (PK) Study of IHL-42X, an Oral Combination Medicine for the Treatment of Obstructive Sleep Apnea

NEW YORK and MELBOURNE, Australia, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing combi...

4 months ago - GlobeNewsWire

Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 1Q 2025

Dallas, Texas--(Newsfile Corp. - December 2, 2024) - Incannex Healthcare Inc. (NASDAQ: IXHL): Stonegate Capital Partners updates their coverage on Incannex Healthcare Inc.  (NASDAQ: IXHL). During 1Q 2...

6 months ago - Newsfile Corp

Incannex Healthcare Inc. Reports Fiscal First Quarter 2025 Financial Results and Business Updates

NEW YORK and MELBOURNE, Australia, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company developing innovative medicines for...

7 months ago - GlobeNewsWire

Incannex Announces Appointment of Dr. Lou Barbato as Chief Medical Officer

NEW YORK and MELBOURNE, Australia, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company developing innovative medicines for...

7 months ago - GlobeNewsWire

Stonegate Initiates Coverage on Incannex Healthcare Inc. (IXHL)

Dallas, Texas--(Newsfile Corp. - October 2, 2024) - Incannex Healthcare Inc. (NASDAQ: IXHL): Stonegate Capital Partners initiates their coverage on Incannex Healthcare Inc. (NASDAQ: IXHL) To view the ...

8 months ago - Newsfile Corp

Incannex Healthcare Inc. Reports Fiscal Full Year 2024 Financial Results and Business Updates

NEW YORK and MELBOURNE, Australia, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company developing innovative medicines fo...

8 months ago - GlobeNewsWire

Sleep Apnea Pill: Quantum Research Survey Shows Sleep Apnea Patients Seeking CPAP Alternatives

A new survey conducted by Quantum Research Group, LLC finds that more than half of patients diagnosed with sleep apnea are not satisfied with their current treatment. Nearly 70 percent of patients exp...

9 months ago - Newsfile Corp

FDA Review of PsiGAD2 IND complete; clinical trial for Psilocybin Assisted Psychotherapy in Patients with Generalised Anxiety Disorder to Proceed

NEW YORK and MELBOURNE, Australia, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (‘Incannex' or the ‘Company'), a clinical-stage pharmaceutical company developing propriet...

10 months ago - GlobeNewsWire

Dosing completed in 115 participant bioavailability/bioequivalence clinical trial for proprietary sleep apnea drug candidate IHL-42X

NEW YORK and MELBOURNE, Australia, July 30, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (‘Incannex' or the ‘Company'), a clinical-stage pharmaceutical company developing propriet...

10 months ago - GlobeNewsWire

Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea

NEW YORK and MELBOURNE, Australia, May 30, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (‘Incannex' or the ‘Company'), a pharmaceutical company developing unique medicinal cannabi...

1 year ago - GlobeNewsWire

Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-O for treatment of opioid use disorder

MELBOURNE, Australia and NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex or the Company), a leading cannabinoid and psychedelic medicine biotechnology com...

1 year ago - GlobeNewsWire

Stonegate Healthcare Partners Releases Report on Potentially Transformative Therapies for Generalized Anxiety Disorder (GAD)

Dallas, Texas--(Newsfile Corp. - May 1, 2024) - Stonegate Healthcare Partners is pleased to announce the publication of its latest report, titled "Potentially Transformative therapies for Generalized ...

1 year ago - Newsfile Corp